SCHEMBL3013472

SCHEMBL3013472

Cc1cccc(Cc2csc(N3CCC(S(=O)(=O)c4cc(Cl)ccc4Cl)CC3)n2)c1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.38
RAB9A P51151 1/20 0.38
FBP1 P09467 1/20 0.35
RECQL P46063 1/20 0.35
TSHR P16473 3/20 0.34
NPSR1 Q6W5P4 3/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
LMNA P02545 2/20 0.34
HTT P42858 1/20 0.34
MAPK1 P28482 1/20 0.34
POLB P06746 2/20 0.34
ALDH1A1 P00352 2/20 0.34
ALDH3A1 P30838 1/20 0.34
CTSS P25774 1/20 0.34
MAPT P10636 3/20 0.33
GAA P10253 2/20 0.33
F2 P00734 1/20 0.33
F2RL3 Q96RI0 1/20 0.33
KDM4E B2RXH2 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015080 0.93 RAB9A (0.38) SMN1; SMN2RAB9ATSHRNPSR1MEN1
SCHEMBL3014184 0.93 RECQL (0.38) SMN1; SMN2RAB9ARECQLTSHRNPSR1
SCHEMBL3013989 0.91 LMNA (0.35) SMN1; SMN2RAB9AMEN1KMT2ALMNA
SCHEMBL3022015 0.91 CTSS (0.42) SMN1; SMN2RAB9AMEN1KMT2ALMNA
SCHEMBL3011124 0.91 SMN1; SMN2 (0.37) SMN1; SMN2RAB9AFBP1RECQLTSHR
SCHEMBL3016060 0.90 RAB9A (0.38) SMN1; SMN2RAB9ARECQLTSHRKMT2A
SCHEMBL3007503 0.89 CTSS (0.41) SMN1; SMN2RAB9AMEN1KMT2ALMNA
SCHEMBL3004586 0.89 RAB9A (0.40) SMN1; SMN2RAB9ATSHRNPSR1MEN1
SCHEMBL3015352 0.88 MAPT (0.43) SMN1; SMN2TSHRNPSR1MEN1KMT2A
SCHEMBL3007230 0.88 SMN1; SMN2 (0.38) SMN1; SMN2RAB9ATSHRNPSR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885FBP1 3444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.